Evidence map›Paper›PMID 41053134›Full record

ArticleScientific reports2025

SKP2 regulates TERT independently of RUNX1/ETO in AML subtypes lacking the t(8,21) translocation via CDKN1B and RB phosphorylation states.

Adam Azlan, Yaashini Rajasegaran, Aliaa Arina Rosli, Mohamed Saleem, Narazah Mohd Yusoff, Mot Yee Yik, Emmanuel Jairaj Moses

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Adam Azlan *Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Bertam, Pulau Pinang, Malaysia.
Yaashini Rajasegaran *Department of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Bertam, Pulau Pinang, Malaysia.
Aliaa Arina RosliDepartment of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Bertam, Pulau Pinang, Malaysia.
Mohamed SaleemCytogenomix Sdn. Bhd.@MyCGxLab, Jalan Burma, 10350, George Town, Pulau Pinang, Malaysia.
Narazah Mohd YusoffAdvanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Bertam, Pulau Pinang, Malaysia.
Mot Yee YikAIMST University, 08100, Bedong, Kedah, Malaysia.
Emmanuel Jairaj MosesDepartment of Biomedical Sciences, Advanced Medical and Dental Institute, Universiti Sains Malaysia, 13200, Bertam, Pulau Pinang, Malaysia. emmanuel_jm@usm.my.

Funding

Ministry of Higher Education, Malaysia FRGS/1/2018/SKK08/USM/02/8Universiti Sains Malaysia 1001/CIPPT/8012265
6 · The paper itself

Abstract

SKP2 has been shown to be essential for cancer growth as SKP2 ubiquitinates various proteins. This event leads to the degradation of proteins crucial towards cancer development from which malignancy trailed. Here we investigated the role of SKP2 in TERT modulation in non t (8,21) AML. Previously, one of the underlying mechanisms of TERT control in t(8,21) AML was elucidated by our research group whereby RUNX1/ETO regulated TERT levels via stabilization of SKP2. Here, in non t(8,21) AML cell lines, direct suppression of SKP2 also led to TERT suppression and concomitant accumulation of CDKN1B. Moreover, SKP2 suppression led to an increase in levels of underphosphorylated RB while no changes in E2F1 levels were observed. Additionally, inverse correlation was observed between FOXO3 (reduced) and c-Myc (increased) protein levels post SKP2 suppression indicating compensatory MYC activation of TERT. However, no changes in MYC occupation on TERT promoter was observed following SKP2 suppression and TERT remain suppressed thus subjugating the notion of TERT related MYC compensatory mechanisms. Collectively, the results of this study show that SKP2 regulate TERT levels independently of RUNX1/ETO in AML subtypes lacking the t(8;21) translocation directly via CDKN1B and RB phosphorylation states.

Indexed as

Core Binding Factor Alpha 2 SubunitCyclin-Dependent Kinase Inhibitor p27Leukemia, Myeloid, AcuteRetinoblastoma ProteinRUNX1 Translocation Partner 1 ProteinS-Phase Kinase-Associated ProteinsTelomeraseTranslocation, GeneticCell Line, TumorChromosomes, Human, Pair 21Forkhead Box Protein O3HumansPhosphorylationCDKN1B protein, humanCore Binding Factor Alpha 2 SubunitCyclin-Dependent Kinase Inhibitor p27Forkhead Box Protein O3Retinoblastoma ProteinRUNX1 protein, humanRUNX1T1 protein, humanRUNX1 Translocation Partner 1 ProteinSKP2 protein, humanS-Phase Kinase-Associated ProteinsTelomeraseTERT protein, humanAcute myeloid leukemia (AML)Non t(8,21) AMLSKP2T(8,21) AMLTERT

Identifiers

PMID41053134
PMCPMC12501274

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.